NucleAI

a leading provider of AI-powered precision oncology technology

NucleAI uses AI to develop precision oncology biomarkers to drive research and treatment decisions. NucleAI’s core technology analyzes large and unique datasets of tissue images using computer vision and machine learning methods to model the spatial characteristics of tissues, such as both the tumor and the patient’s immune system cells, creating unique signatures that are predictive of patients response. The company is headquartered in Tel Aviv, Israel.

Why we invested in NucleAI

In oncology, drug development is diving deeper and deeper into specific tumor sub-types and patient sub-groups. But how do you make sure that the patients that would benefit most of your treatment receive it? Pathology slides, and paticularly tumor biopsies, contain a wealth of pertinent information that may be captured/measured easily with image analysis to generate new biomarkers. NucleAI spoke to us with their ultimate technical skills and we decided to join the forces, for developing treatments that work better.

Are you also an entrepreneur seeking funding?

Discover how we can help you bring your ambition to life

Contact us

Company News

All News

Press Releases

All Press Releases